Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-263 · 4 trials · 7 indications
| Arm | Type | Description |
|---|---|---|
| Arm A (ABT-263 and Ketoconozole) | EXPERIMENTAL | - |
| Sequence I | EXPERIMENTAL | - |
| Sequence II | EXPERIMENTAL | - |
| Sequence III | EXPERIMENTAL | - |
| docetaxel +ABT-263 | EXPERIMENTAL | - |
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | EXPERIMENTAL | - |
| 4 | EXPERIMENTAL | - |
| 5 | EXPERIMENTAL | - |
| 6 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ABT-263 | DRUG | Subjects will be dosed with ABT-263, then dosed with ABT-263 in combination with Ketoconazole. |
| Ketoconazole | DRUG | Subjects will be dosed with ABT-263, then dosed with ABT-263 in combination with Ketoconazole. |
| Docetaxel | DRUG | 75 mg/m2 will be given by intravenous infusion on day 1 of each 21 -day cycle. 30 mg/m2 will be given by intravenous infusion on day 1, 8, 15 of each 28 -day cycle. |
Inclusion Criteria: * 18 years of age or older. * Has a non-hematologic malignancy (radiographic, histologic, or cytologic confirmation), or hematologic malignancy (histologic or cytologic confirmation) that is either: relapsed or refractory to standard therapy, failed at least one prior therapy or...
ABT-263 is an investigational small molecule being studied for use in chronic lymphocytic leukemia, lymphoma, solid tumors, and in healthy female subjects for bioavailability studies. It is being developed by Abbott Laboratories and is currently in Phase 1 clinical development.
ABT-263 is a small molecule being developed by Abbott Laboratories. The specific molecular target of ABT-263 has not been disclosed in the available information. It is being studied in oncology indications including chronic lymphocytic leukemia, lymphoma, and solid tumors.
ABT-263 is being developed by Abbott Laboratories, a company traded under the ticker symbol ABT. The drug is currently in Phase 1 clinical development for oncology indications including chronic lymphocytic leukemia, lymphoma, and solid tumors.
ABT-263 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. All completed trials for ABT-263 were Phase 1 studies, and there are no active trials currently listed.
ABT-263 has completed four Phase 1 clinical trials. These include NCT00743028, a bioavailability study in chronic lymphocytic leukemia and lymphomas; NCT00888108, a safety and pharmacokinetic study in solid tumors; NCT01021358, a drug interaction study with ketoconazole; and NCT01053520, a bioavailability study in healthy female subjects.
Yes, ABT-263 is also known as Navitoclax. One of its completed clinical trials, NCT01021358, is titled 'A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax).' The drug is being developed by Abbott Laboratories for oncology indications.